Denise Myshko

Andrew Mellin, M.D., discusses Surescripts’ pilot program for prior authorization system, which pulls clinical data from EHRs and matches it against payer criteria.

There have been tremendous advances in specialty drugs, but those advances have also brought a lot of complexity for payers. Payers are considering new strategies for their specialty benefit.

Rebates aren’t disappearing, but PSG's 2026 survey suggests payers increasingly favor lower net costs, biosimilars and price transparency over traditional specialty drug rebate programs.

This action follows an Executive Order issued earlier this week to speed review of psychedelic drugs that have shown potential to treat serious mental health issues

Major health insurers say they have cut prior authorizations, but the AMA says physicians report that the burden of prior authorization remains high.

Regeneron is making Otarmeni, which treats patients with biallelic variants in the OTOF gene, available at no cost. This is the second therapy that was approved under the FDA’s new National Priority Voucher program.

In an earning call, UnitedHealth Group executives, including CEO Stephen Hemsley, discussed the company’s strategy, which is focused value-based care, its Medicare Advantage programs transparency, AI and its transparency efforts.

Timely diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) could potentially reduce excess healthcare utilization and spending, according to a poster at AMCP annual meeting 2026 in Nashville.

Evernorth’s Nicole A. Caffiero said specialty drugs dominate the pipeline, FDA approvals and the expenditures on pharmaceuticals during a keynote presentation at the AMCP annual meeting.

The Maximum Fair Price (MFP), established by the Inflation Reduction Act, and the Most Favored Nation policy are reshaping how drugs are priced, paid for, and accessed.

The anti-obesity market is now the fourth largest and is expected to grow. The pipeline contains 190 obesity-related products, IQVIA’s Scott Biggs said.

Navitus Health Solutions saw both overall savings and reduced patient costs from the switch to the adalimumab biosimilars. Vanderbilt Health, however, experienced increased adverse events after the biosimilar conversation and further switching to other biosimilars or therapies.

Evaluating the costs and outcomes of alternative funding programs requires balancing financial objectives with patient considerations.

A convergence of legislative and judicial actions is creating PBM transparency, adding fiduciary responsibility, and addressing anti-competitive behavior, participants Jeffrey Hogan and Chad Worz, Pharm.D., said during a webinar sponsored by Managed Healthcare Executive and Drug Topics.

Additionally, Orlando Health — Health Central Hospital is building a new cardiac catheterization laboratory with specialized electrophysiology equipment.

PBMs have launched clinical programs pairing GLP-1 prescriptions with pharmacist coaching, nutrition support, behavioral health partnerships, and digital tools to improve adherence and outcomes.

Yuvezzi treats presbyopia, or blurry vision due to aging, and is available at retail pharmacies or PHIL, an ePharmacy platform.

Lenox Hill Hospital’s controversial $2 billion redevelopment includes a new mental health clinic, a shorter tower, and expanded emergency, surgical, and maternity facilities.

USF Health researchers have discovered how opioid receptors work in reverse, which could allow for medications to boost pain relief without causing dangerous side effects.

A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid cardiomyopathy, with no new safety concerns identified.

Novo Nordisk is offering the subscriptions through telehealth providers Ro, WeightWatchers and LifeMD. Others are expected to follow.

Preliminary data from a preclinical study show that vialinin-A, a compound isolated from Chinese mushrooms, is an antioxidant that has an anti-inflammatory effect.

Adults with moderate atopic dermatitis reported rapid itch relief, better sleep, and improved daily functioning after eight weeks using Opzelura topical cream.

A new patient survey reveals gaps in treatment persistence and awareness among patients with vitiligo.

Litifilimab, a monoclonal antibody that reduces type-I interferon production and inflammation, has the potential to be a first-in-class targeted therapy for patients with cutaneous lupus.